NasdaqGS - Delayed Quote USD

NovoCure Limited (NVCR)

12.64 +0.41 (+3.31%)
At close: April 26 at 4:00 PM EDT
12.50 -0.14 (-1.07%)
After hours: April 26 at 7:50 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. William F. Doyle Executive Chairman 1.52M -- 1962
Mr. Asaf Danziger CEO & Director 1.7M -- 1966
Ms. Ashley Cordova Chief Financial Officer 933.39k 461.89k 1979
Mr. Wilhelmus C. M. Groenhuysen Chief Operating Officer 1.01M -- 1958
Mr. Frank Leonard Executive VP & President of Novocure Oncology 723.1k 457.08k --
Prof. Yoram Palti M.D., Ph.D. Founder & CTO 282.51k -- 1938
Dr. Moshe Giladi Ph.D. Chief Science Officer -- -- 1970
Ms. Ingrid Goldberg VP of Investor Relations -- -- --
Mr. Barak Ben Arye General Counsel -- -- 1977
Mr. Michael Puri Chief Human Resources Officer -- -- 1969

NovoCure Limited

No. 4 The Forum
Second Floor Grenville Street
Saint Helier, JE2 4UF
Jersey
44 15 3475 6700 https://www.novocure.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
1,453

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Corporate Governance

NovoCure Limited’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
NovoCure Limited Earnings Call

Related Tickers

NARI Inari Medical, Inc.
38.42
+0.92%
 
MASI Masimo Corporation
136.14
+0.67%
 
SWAV Shockwave Medical, Inc.
330.00
+0.31%
 
QDEL QuidelOrtho Corporation
39.64
-0.13%
 
TMDX TransMedics Group, Inc.
92.08
+3.17%
 
INSP Inspire Medical Systems, Inc.
237.45
+2.79%
 
INMD InMode Ltd.
17.14
+0.71%
 
PODD Insulet Corporation
166.19
+1.23%
 
TNDM Tandem Diabetes Care, Inc.
35.24
-0.90%
 
SILK Silk Road Medical, Inc
17.80
+0.85%